Receipt of Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis in Medicare Managed Care Plans

被引:108
|
作者
Schmajuk, Gabriela [1 ]
Trivedi, Amal N. [2 ]
Solomon, Daniel H. [3 ]
Yelin, Edward [4 ]
Trupin, Laura [4 ]
Chakravarty, Eliza F. [1 ]
Yazdany, Jinoos [4 ]
机构
[1] Stanford Univ, Dept Med, Div Rheumatol, Stanford, CA 94304 USA
[2] Brown Univ, Dept Community Hlth & Med, Providence, RI 02912 USA
[3] Harvard Univ, Brigham & Womens Hosp, Dept Med, Div Rheumatol, Boston, MA 02115 USA
[4] Univ Calif San Francisco, Dept Med, Div Rheumatol, San Francisco, CA USA
来源
基金
美国医疗保健研究与质量局; 美国国家卫生研究院;
关键词
QUALITY-OF-CARE; HEALTH PLANS; DISPARITIES; OUTCOMES; DATABASE; COST; BENEFICIARIES; NEIGHBORHOOD; MEDICATIONS; AMERICAN;
D O I
10.1001/jama.2011.67
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context In 2005, the Healthcare Effectiveness Data and Information Set (HEDIS) introduced a quality measure to assess the receipt of disease-modifying antirheumatic drugs (DMARDs) among patients with rheumatoid arthritis (RA). Objective To identify sociodemographic, community, and health plan factors associated with DMARD receipt among Medicare managed care enrollees. Design, Setting, and Participants We analyzed individual-level HEDIS data for 93 143 patients who were at least 65 years old with at least 2 diagnoses of RA within a measurement year (during 2005-2008). Logistic regression models with generalized estimating equations were used to determine factors associated with DMARD receipt and logistic regression was used to adjust health plan performance for case mix. Main Outcome Measures Receipt or nonreceipt of DMARD. Results The mean age of patients was 74 years; 75% were women and 82% were white. Overall performance on the HEDIS measure for RA was 59% in 2005, increasing to 67% in 2008 (P for trend <.001). The largest difference in performance was based on age: patients aged 85 years and older had a 30 percentage point lower rate of DMARD receipt (95% confidence interval [CI], -29 to -32 points; P<.001), compared with patients 65 to 69 years of age, even after adjusting for other factors. Lower percentage point rates were also found for patients who were men (-3 points; 95% CI, -5 to -2 points; P<.001), of black race (-4 points; 95% CI, -6 to -2 points; P<.001), with low personal income (-6 points; 95% CI, -8 to -5 points; P<.001), with the lowest zip code-based socioeconomic status (-4 points; 95% CI, -6 to 2 points; P<.001), or enrolled in for-profit health plans (-4 points; 95% CI, -7 to 0 points; P<.001); and in the Middle Atlantic region (-7 points; 95% CI, -13 to -2 points; P<.001) and South Atlantic regions (-11 points; 95% CI, -20 to -3 points; P<.001) as compared with the Pacific region. Performance varied widely by health plan, ranging from 16% to 87%. Conclusions Among Medicare managed care enrollees carrying a diagnosis of RA between 2005 and 2008, 63% received a DMARD. Receipt of DMARDs varied based on demographic factors, socioeconomic status, geographic location, and health plan. JAMA. 2011;305(5):480-486 www.jama.com
引用
收藏
页码:480 / 486
页数:7
相关论文
共 50 条
  • [11] Disease-modifying antirheumatic drugs in rheumatoid arthritis patients with a history of colorectal cancer
    Kleinert, S.
    Waldner, M.
    Wendler, J.
    Kunzmann, V.
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2016, 75 (01): : 41 - 46
  • [12] Utilization Patterns of Disease-Modifying Antirheumatic Drugs in Elderly Rheumatoid Arthritis Patients
    Jin, Xue-Mei
    Lee, Joongyub
    Choi, Nam-Kyong
    Seong, Jong-Mi
    Shin, Ju-Young
    Kim, Ye-Jee
    Kim, Mi-Sook
    Yang, Bo Ram
    Park, Byung-Joo
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2014, 29 (02) : 210 - 216
  • [13] Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
    Xia, Yunfei
    Yin, Rulan
    Fu, Ting
    Zhang, Lijuan
    Zhang, Qiuxiang
    Guo, Genkai
    Li, Liren
    Gu, Zhifeng
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2016, 10 : 735 - 742
  • [14] High Degree of Nonadherence to Disease-modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
    Rauscher, Veronika
    Englbrecht, Matthias
    van der Heijde, Desiree
    Schett, Georg
    Hueber, Axel J.
    [J]. JOURNAL OF RHEUMATOLOGY, 2015, 42 (03) : 386 - 390
  • [15] Corticosteroids and disease-modifying antirheumatic drugs for coronavirus disease 2019 in patients with rheumatoid arthritis
    Chen, Yu-Han
    Lee, Yuan-Ti
    Ma, Kevin Sheng-Kai
    [J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (07) : 1391 - 1392
  • [16] Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs
    Sizova, Lyudmila
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 66 (02) : 173 - 178
  • [17] THE EARLY USE OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID-ARTHRITIS
    MONGAN, ES
    [J]. ARTHRITIS AND RHEUMATISM, 1990, 33 (03): : 451 - 451
  • [18] Disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: Medical education
    Top, Cihan
    Terekeci, Hakan
    [J]. TURKIYE KLINIKLERI TIP BILIMLERI DERGISI, 2008, 28 (03): : 387 - 398
  • [19] DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID-ARTHRITIS - CURRENT CONCEPTS
    EMERY, P
    LUQMANI, R
    GORDON, C
    [J]. BRITISH JOURNAL OF CLINICAL PRACTICE, 1994, 48 (02): : 82 - 86
  • [20] Predictors of Stopping and Starting Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis
    Solomon, Daniel H.
    Tonner, Chris
    Lu, Bing
    Kim, Seoyoung C.
    Ayanian, John Z.
    Brookhart, M. Alan
    Katz, Jeffrey N.
    Yelin, Ed
    [J]. ARTHRITIS CARE & RESEARCH, 2014, 66 (08) : 1152 - 1158